Cholangiocarcinoma and Gallbladder Cancer Studies
Open access
Peer reviewed
Abstract
Abstract
Advanced intrahepatic cholangiocarcinoma (ICC) may be liver-confined or liver-dominant after curative resection is no longer feasible. This distribution supports a role for locoregional therapy (LRT), whereas occult or established extrahepatic disease still requires systemic control. This narrative review integrates the most recent clinical and mechanistic evidence for combining LRT with chemotherapy, immune checkpoint inhibition, molecularly targeted treatment, and cellular therapy. Randomized phase III biliary tract cancer trials support gemcitabine-cisplatin plus durvalumab or pembrolizumab as first-line systemic therapy, but the primary analyses improved median overall survival by only 1.3 and 1.8 months. Evidence for adding LRT is less mature and heterogeneous. Prospective single-arm studies of yttrium-90 radioembolization, hepatic arterial infusion, radiotherapy, and cryoablation-based combinations report activity in selected ICC populations, but most lack a contemporary control and cannot isolate the contribution of LRT. No biomarker has validated the incremental benefit of a specific LRT. Clinical development should therefore specify the LRT modality and exposure, disease distribution, systemic backbone, treatment intent, and safety boundary. Routine adoption requires reproducible protocols, comparative survival and safety endpoints, and paired biomarker collection.
Direct answer
What can I do from this paper page?
Use this page to scan "Integrating locoregional therapy with systemic and emerging cellular therapies in advanced intrahepatic cholangiocarcinoma" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Cholangiocarcinoma and Gallbladder Cancer Studies research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Zhang2026Integrating,
title = {Integrating locoregional therapy with systemic and emerging cellular therapies in advanced intrahepatic cholangiocarcinoma},
author = {Lihua Zhang and Mengqi Zhang and Zengjin Wen and Xiaoxuan Li and Wensheng Qiu},
journal = {Discover Oncology},
year = {2026},
doi = {10.1007/s12672-026-05832-1},
url = {https://doi.org/10.1007/s12672-026-05832-1}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Cholangiocarcinoma and Gallbladder Cancer Studies research papers?
Follow Cholangiocarcinoma and Gallbladder Cancer Studies research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Integrating locoregional therapy with systemic and emerging cellular therapies in advanced intrahepatic cholangiocarcinoma. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app